

CLAIMS

1. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of
 - 5 *N*-(6-aminoheptyl)-4-bromobenzamidine (compound #145),

4-bromo-*N*-{7-[(4-bromobenzimidoyl)-amino]-heptyl}-benzamide (compound #146),

N-hydroxy-4-(9-hydroxyaminononyloxy)-benzamidine (compound #147),
10 *N*-[7-(4-carbamimidoylbenzoylamino)-heptyl]-terephthalamic acid ethyl ester (compound #148),

N-[9-(4-carbamimidoyl-benzoylamino)-nonyl]-terephthalamic acid ethyl ester
15 (compound #149),

4,4'-(pentamethylenediamidino)di(*p*-bromobenzene) (compound #150),

4,4'-(nonamethylenediamidino)di(*p*-bromobenzene) (compound #151),
20 4,4'-(nonamethylenediamidino)di(*p*-methoxybenzene) (compound #152),

4-methoxy-*N*-{2-[2-(4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-ethyl}-benzamidine
(compound #153),
25 4,4'-(pentamethylenediamidino)di(*p*-methoxybenzene) (compound #154),

2,2'-(*p*-amidinophenylcarboxamido)-*N,N*-diethyl-*p*-amidinobenzamide (compound
#155),
30 {4-[5-(*p*-aminophenoxy)-pentyloxy]-phenyl}-(4,5-dihydro-1*H*-imidazol-2-yl)-amine
(compound #156),


4,4'-(nonamethylenedisulfamyl)di(amidinobenzene) (compound #158),

3,3'-(pentamethylenediaminocarbonyl)di(amidinobenzene) (compound #159),

4,4'-(tetramethylenediaminocarbonyl)di(amidinobenzene) (compound #160), and


pharmaceutically acceptable salts thereof.

2. The method according to claim 1, wherein said subject is in need of treating or preventing of said amyloid-related disease.
3. The method according to any one of claims 1-2, wherein said amyloid-related disease is associated with IAPP.
4. The method according to any one of claims 1-2, wherein said amyloid-related disease is associated with β -amyloid.
5. The method according to any one of claims 1-4, wherein said amyloid-related disease is, Alzheimer's disease, Down's syndrome, type II diabetes, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.
6. The method according to any one of claims 1-5, wherein said compound is adapted to be administered orally.
7. The method according to claim 2, where said subject is a human.
8. A chemical compound having the following structure:




and pharmaceutically acceptable salts thereof.

9. A chemical compound having the following structure:




- 5 and pharmaceutically acceptable salts thereof.

10. A chemical compound having the following structure:




- 10 and pharmaceutically acceptable salts thereof.

11. A chemical compound having the following structure:




- 15 and pharmaceutically acceptable salts thereof.

12. A chemical compound having the following structure:




- 20 and pharmaceutically acceptable salts thereof.

13. A chemical compound having the following structure:




- 5 and pharmaceutically acceptable salts thereof.

14. A chemical compound having the following structure:




- 10 and pharmaceutically acceptable salts thereof.

15. A chemical compound having the following structure:




- 15 and pharmaceutically acceptable salts thereof.

16. A chemical compound having the following structure:




- 20 and pharmaceutically acceptable salts thereof.

17. A chemical compound having the following structure:




- 5 and pharmaceutically acceptable salts thereof.

18. A chemical compound having the following structure:




- 10 and pharmaceutically acceptable salts thereof.

19. A chemical compound having the following structure:




- 15 and pharmaceutically acceptable salts thereof.

20. A chemical compound having the following structure:




- 20 and pharmaceutically acceptable salts thereof.

21. A chemical compound having the following structure:



- 5 and pharmaceutically acceptable salts thereof.

22. A chemical compound having the following structure:



- 10 and pharmaceutically acceptable salts thereof.

23. A pharmaceutical composition comprising a compound according to any one of claims 8-22.

24. The composition according to claim 23, further comprising a pharmaceutically acceptable vehicle.

- 15 25. A pharmaceutical composition for the treatment or prevention of an amyloid-related disease comprising a therapeutically effective amount of a compound according to any one of claims 8-22.

- 20 26. The composition according to claim 25, wherein said amyloid-related disease is Alzheimer's disease, Down's syndrome, type II diabetes, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.